Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 5,128 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: Obesity
Interventions: Calcium Carbonate; Dietary Supplement
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Hypertension
Interventions: BSF 208075; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: Cystic Fibrosis Lung
Interventions: 4D-710; Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more

Conditions: Distress, Depression, Grief
Interventions: Psilocybin, Modified brief Supportive Expressive Group Therapy; Drug · Behavioral
Lead sponsor: Joshua Woolley; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, Sotatercept, SOC; Drug · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 12
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more

Conditions: Epilepsy, Depression, Anxiety, Emotions
Interventions: Viewing visual stimuli and electrical stimulation of the brain; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Erythropoietic Protoporphyria
Interventions: Afamelanotide, Placebo; Drug
Lead sponsor: Clinuvel Pharmaceuticals Limited; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Detroit, Michigan + 4 more

Conditions: Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
Interventions: AG10, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 13
States / cities: Beverly Hills, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Hidradenitis Suppurativa
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer Disease
Interventions: ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 27
States / cities: Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more

Conditions: Traumatic Brain Injury (TBI), Hazardous and Harmful Alcohol Use
Interventions: Medical Management Counseling, N-acetylcysteine, Placebo; Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Fibrosing Colonopathy
Interventions: ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy; Biological · Other
Lead sponsor: AbbVie; Industry
Eligibility: 0 Months to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 123
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Chemotherapy, Pembrolizumab, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 566
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more

Conditions: Graft Versus Host Disease
Interventions: Prochymal®, Placebo, Standard of Care for GVHD; Biological · Drug
Lead sponsor: Mesoblast, Inc.; Industry
Eligibility: 6 Months to 70 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 47
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more

Conditions: Metastatic Breast Cancer
Interventions: PLX3397, Eribulin; Drug
Lead sponsor: Hope Rugo, MD; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Durham, North Carolina • Nashville, Tennessee

Conditions: Relapsed or Refractory Solid Tumors
Interventions: OMP-52M51; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Detroit, Michigan + 2 more

Conditions: Dyskinetic Cerebral Palsy, Dystonic Cerebral Palsy
Interventions: DBS; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 7 Years to 25 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: In-Stent Restenosis
Interventions: AGENT DCB, PTCA balloon catheter; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 40
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 33 more

Conditions: Spine, Pain, Spine Surgery, Spine Surgery With Neuromonitoring, Spine Surgery With Motor Evoked Potential Monitoring, Spine Fusion
Interventions: Magnesium sulfate administration; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions: NBTXR3, SABR, Nivolumab, Pembrolizumab; Drug · Radiation
Lead sponsor: Nanobiotix; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 13
States / cities: San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more

Conditions: Arteriovenous Fistula
Interventions: SRM003, Participating Site's standard practice; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 41 more

Conditions: Nocturia
Interventions: TolterodineTartrate ER, Mirabegron, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Dependence, Tobacco Smoking
Interventions: Smoke-free home resident intervention, Lay Health Worker coaching; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Neoplasms, Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer
Interventions: Not listed
Lead sponsor: Precision Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more

Search by objective public record fields.

Calcium and Lipid Metabolism

Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

4D-710 in Adult Patients With Cystic Fibrosis

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

Spatiotemporal Dynamics of the Human Emotion Network

Phase III Confirmatory Study in Erythropoietic Protoporphyria

Study of AG10 in Amyloid Cardiomyopathy

Clinical and Biological Characteristics of Hidradenitis Suppurativa

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Cerebellar Deep Brain Stimulation for Movement Disorders in Cerebral Palsy in Children and Young Adults

A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)

Effect of Magnesium on Neuromonitoring

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access

Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH

Smoke-free Home Study in Subsidized Housing

ChemoFx® PRO - A Post-Market Data Collection Study